Medical News

Non-Albumin Proteinuria: A Marker to Stratify T2DM Patients with Early DKD

Albuminuria and urinary N-acetyl-β-D-glucosaminidase (uNAG) are established markers for progression of diabetic kidney disease. But little is known...

18 Mar, 2019

 
Email this page
Identifying the Risk Factors Linked to The Presence of Foot Ulcer in Patients with Diabetes

A recent study conducted in Africa, underscored the importance of considering more foot-specific parameters for identifying the risk of diabetic...

15 Mar, 2019

 
Email this page
Novel High Fiber White Rice, A Better Alternative to Regular White Rice in Asian Indians at High Risk of Diabetes

A novel Indian study that used continuous glucose monitoring to ascertain the 24-hour glycemic response of the novel high fiber white rice (HFWR) vs...

11 Mar, 2019

 
Email this page
Vildagliptin does not Increase/Exacerbate Diabetic Complications, Reports a Japanese Study

Type-2 diabetes mellitus (T2DM) is associated with micro- and macro-vascular complications. Although good glycemic control suppresses the onset of...

07 Mar, 2019

 
Email this page

Key Trials

Regression in Albuminuria is Associated with Reduction in All-Cause Mortality in Insulin-Treated T2DM Patients

This large-scale study reaffirms albuminuria to be an independent marker of subsequent all-cause mortality and cardiovascular events in insulin-...

Sustained Reduction in Incident Diabetes Even 3 Years after Withdrawal of Active SMS-based Lifestyle Intervention

An Indian study demonstrates persistent reduction in risk of T2DM even 3 years after withdrawal of active SMS-based lifestyle intervention.  

Impact of Diabetes on Kidney Function Decline: Results from A 26-year Follow up of Community-based Cohort

The prospective, community-based 26-year follow-up study looks at the impact of diabetes on kidney function decline in a general population.  

Preservation of Beta-cell Function: Daily Metformin vs. Intermittent Intensive Insulin Therapy

Metformin is superior to intermittent IIT for preservation of beta-cell function and better glycemic control in early Type-2 diabetes patients.

Our Publications

Mind Matters (Issue 3) - Role of Escitalopram in the Treatment of Comorbid Depression and Diabetes

The presence of depression in patients with diabetes mellitus is of vast importance, as it is usually associated with poor disease control, adverse...

Diabetes Management Series: Cholesterol

Most relevant information on management of dyslipidemia, a common comorbidity observed in diabetes patients, has been summarised in this document.

Drug Therapy for Management of Hyperglycaemia

Brief information on the treatment strategy and selection of oral antihyperglycemic agents in type 2 diabetes is summarised in this document.

Diabetes Management Series: Hypertension

Hypertension elevates the risk of micro-and macro-vascular complications in diabetes. Here is a summary on the BP treatment goals in diabetes...

Slide Library

Clinical Practice Recommendations: ADA 2014

This slide set summarizes the key 2014 clinical practice recommendations of the American Diabetes Association (ADA) on the screening, diagnosis and...

 
Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

 
Email this page
Treating Hypertension in Diabetics : Optimal Selection of Antihypertensive Therapy

Hypertension affects 20%-60% of diabetics. It substantially increases the risk of macrovascular and microvascular complications in diabetes. This...

 
Email this page
The ‘Four Facets’ of Glucose Control: Focus on Voglibose and Metformin Combination

This slide set addresses the need to progress from the glucose triad to the glucose pyramid for achieving steady glucose control. The effectiveness...

 
Email this page

Poll

Which is your preferred DPP4 inhibitor for your type 2 diabetes patients with ESRD?
Sitagliptin
22% (4 votes)
Vildagliptin
22% (4 votes)
Linagliptin
50% (9 votes)
No specific choice
6% (1 vote)
Don’t prefer a DPP4 inhibitor
0% (0 votes)
Total votes: 18